Generic placeholder image

Current Neurovascular Research

Author(s): Jianhao Xiao, Xiaodong Li, Qian Yuan, Simiao Zhang, Kun Qu, Boyi Wu, Yunliang Wang* and Shiwei Duan*

DOI: 10.2174/1567202616666190412154407

DownloadDownload PDF Flyer Cite As
PON1 Hypermethylation and PON3 Hypomethylation are Associated with Risk of Cerebral Infarction

Page: [115 - 122] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Objective: Paraoxonase (PON) family genes are closely related to the etiology and prognosis of cerebral infarction. This study explored the association of the promoter methylation of PON family genes (PON1, PON2 and PON3) with the risk of cerebral infarction.

Materials and Methods: In this study, 152 patients with confirmed cerebral infarction were selected as the case group, and 152 healthy controls were selected as the control group. The quantitative methylation-specific PCR (qMSP) was used to determine the promoter methylation levels of PON1, PON2 and PON3 genes. The methylation level was expressed as a methylation reference percentage (PMR).

Results: Our results indicated that PON1 methylation was significantly higher in the case group than in the control group (P = 0.0001). On the contrary, PON3 methylation was significantly lower in the case group than in the control group (P = 0.002). In addition, we found that PON2 gene had a very low level of methylation in both case and control groups (PMR = 0). Subgroup analysis showed that PON1 and PON3 methylation were associated with cerebral infarction only in males (PON1, P = 0.0002; PON3, P = 0.007). Interestingly, the methylation levels of PON1 and PON3 were correlated with each other (case: r = 0.418, P = 0.0001; control: r = 0.3, P = 0.0002). Further multiple regression analysis suggested that elevated methylation levels of PON3 were a protective factor for cerebral infarction [OR (95%CI) = 0.979 (0.96, 0.999), β = -0.021, P = 0.035)], highdensity lipoprotein (HDL) and uric acid (UA) also were protective factors for cerebral infarction [HDL, OR (95% CI) = 0.01 (0.003, 0.033), P < 0.0001); UA, OR (95% CI) = 0.995 (0.991, 0.998), P = 0.003)]. The ROC curve analysis found that the combination of PON3, HDL, and UA had a good predictive power for cerebral infarction (AUC=0.878, 95% CI=0.839-0.918, sensitivity 73.7%, specificity 89.7%, P < 0.0001).

Conclusion: PON1 and PON3 promoter methylation levels in peripheral blood were closely related. PON1 and PON3 methylation were associated with the risk of cerebral infarction in men. PON3 promoter methylation combined with HDL and UA could be used as potential biomarkers for the diagnosis of cerebral infarction.

Keywords: Cerebral infarction, DNA methylation, PON1, PON3, promoter, high-density lipoprotein (HDL), uric acid (UA).

[1]
Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the global burden of ischemic and hemorrhagic stroke in 1990-2013: The GBD 2013 study. Neuroepidemiology 2015; 45(3): 161-76.
[2]
Global Burden of Disease Study C. Global. regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995): 743-800.
[3]
Soriano-Tarraga C, Jimenez-Conde J, Giralt-Steinhauer E, et al. Global DNA methylation of ischemic stroke subtypes. PLoS One 2014; 9(4)e96543
[4]
Krupinski J, Carrera C, Muino E, et al. DNA Methylation in Stroke. update of latest advances. Comput Struct Biotechnol J 2018; 16: 1-5.
[5]
Hu Z, Zhong B, Tan J, et al. The emerging role of epigenetics in cerebral ischemia. Mol Neurobiol 2017; 54(3): 1887-905.
[6]
Zhang G, Li W, Li Z, et al. Association between paraoxonase gene and stroke in the Han Chinese population. BMC Med Genet 2013; 14: 16.
[7]
Osawa K, Trejo MEP, Nakanishi R, et al. Coronary artery calcium and carotid artery intima-media thickness for the prediction of stroke and benefit from statins. Eur J Prev Cardiol 2018; 25(18): 1980-7.
[8]
Rajkovic MG, Rumora L, Barisic K. The paraoxonase 1, 2 and 3 in humans. Biochem Med 2011; 21(2): 122-30.
[9]
Precourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: Physiologic roles, actions and regulation. Atherosclerosis 2011; 214(1): 20-36.
[10]
Singh K, Singh R, Chandra S, et al. Paraoxonase-1 is a better indicator than HDL of atherosclerosis-A pilot study in North Indian population. Diabet Metabol Syndr 2018; 12(3): 275-8.
[11]
Borovkova EI, Antipova NV, Komeenko TV, et al. Paraoxonase: The universal factor of antioxidant defense in human body. Vestn Ross Akad Med Nauk 2017; 72(1): 5-10.
[12]
Matthews AR, Sutter ME, Rentz DE. Serum paraoxonase-1 (PON-1) genotype and exposure to organophosphorous insectides--is there a high-risk population? J Med Toxicol 2011; 7(3): 243-7.
[13]
Samouilidou E, Bountou E, Papandroulaki F, et al. Serum endocan levels are associated with paraoxonase 1 concentration in patients with chronic kidney disease. Ther Apher Dial 2018; 22(4): 325-31.
[14]
Meller A, Golab-Janowska M, Paczkowska E, et al. Reduced hemoglobin levels combined with an increased plasma concentration of vasoconstrictive endothelin-1 are strongly associated with poor outcome during acute ischemic stroke. Curr Neurovasc Res 2018; 15(3): 193-203.
[15]
Gokdemir MT, Karakilcik AZ, Gokdemir GS. Prognostic importance of paraoxonase, arylesterase and mean platelet volume efficiency in acute ischaemic stroke. JPMA 2017; 67(11): 1679-83.
[16]
Walsh KB, Hart K, Roll S, et al. Apolipoprotein A-I and Paraoxonase-1 are potential blood biomarkers for ischemic stroke diagnosis. J Stroke Cerebrovasc Dis 2016; 25(6): 1360-5.
[17]
Costa LG, de Laat R, Dao K, et al. Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection. Neurotoxicology 2014; 43: 3-9.
[18]
Li W, Kennedy D, Shao Z, et al. Paraoxonase 2 prevents the development of heart failure. Free Radic Biol Med 2018; 121: 117-26.
[19]
Rull A, Garcia R, Fernandez-Sender L, et al. Serum paraoxonase-3 concentration is associated with insulin sensitivity in peripheral artery disease and with inflammation in coronary artery disease. Atherosclerosis 2012; 220(2): 545-51.
[20]
Howard G, Wagenknecht LE, Kernan WN, et al. Racial differences in the association of insulin resistance with stroke risk: The REasons for Geographic And Racial Differences in Stroke (REGARDS) study. Stroke 2014; 45(8): 2257-62.
[21]
Kamide K, Rakugi H, Nakano N, et al. Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. Am J Hypertens 1997; 10(11): 1245-9.
[22]
Hill MD. Stroke and diabetes mellitus. Handb Clin Neurol 2014; 126: 167-74.
[23]
O’Collins VE, Donnan GA, Macleod MR, et al. Hypertension and experimental stroke therapies. J Cereb Blood Flow Metab 2013; 33(8): 1141-7.
[24]
Lei HP, Yu XY, Wu H, et al. Effects of PON1 gene promoter dna methylation and genetic variations on the clinical outcomes of dual antiplatelet therapy for patients undergoing percutaneous coronary intervention. Clin Pharmacokinet 2018; 57(7): 817-29.
[25]
Gomez-Uriz AM, Goyenechea E, Campion J, et al. Epigenetic patterns of two gene promoters (TNF-alpha and PON) in stroke considering obesity condition and dietary intake. J Physiol Biochem 2014; 70(2): 603-14.
[26]
Zhou C, Pan R, Hu H, et al. TNFRSF10C methylation is a new epigenetic biomarker for colorectal cancer. PeerJ 2018; 6e5336
[27]
Zhang Y, Tuomilehto J, Jousilahti P, et al. Total and high-density lipoprotein cholesterol and stroke risk. Stroke 2012; 43(7): 1768-74.
[28]
Reina SA, Llabre MM, Allison MA, et al. HDL cholesterol and stroke risk: The multi-ethnic study of atherosclerosis. Atherosclerosis 2015; 243(1): 314-9.
[29]
Llull L, Laredo C, Renu A, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke 2015; 46(8): 2162-7.
[30]
Furlong CE, Marsillach J, Jarvik GP, et al. Paraoxonases-1, -2 and -3: What are their functions? Chem Biol Interact 2016; 259(Pt B): 51-62.
[31]
Zhu H, Zhao T, Liu J. Role of Paraoxonase 1 activity and oxidative/antioxidative stress markers in patients with acute cerebral infarction. Clin Lab 2018; 64(6): 1049-53.
[32]
Simon RP. Epigenetic modulation of gene expression governs the brain’s response to injury. Neurosci Lett 2016; 625: 16-9.
[33]
Ng CJ, Wadleigh DJ, Gangopadhyay A, et al. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 2001; 276(48): 44444-9.
[34]
Draganov DI, Stetson PL, Watson CE, et al. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275(43): 33435-42.
[35]
Sanghera DK, Manzi S, Minster RL, et al. Genetic variation in the paraoxonase-3 (PON3) gene is associated with serum PON1 activity. Annals of human genetics 2008; 72(Pt 1): 72-81.
[36]
Chella Krishnan K, Mehrabian M, Lusis AJ. Sex differences in metabolism and cardiometabolic disorders. Current opinion in lipidology 2018; 29(5): 404-10.
[37]
Teiber JF, Billecke SS, La Du BN, et al. Estrogen esters as substrates for human paraoxonases. Arch Biochem Biophys 2007; 461(1): 24-9.
[38]
Giordano G, Tait L, Furlong CE, et al. Gender differences in brain susceptibility to oxidative stress are mediated by levels of paraoxonase-2 expression. Free Radic Biol Med 2013; 58: 98-108.
[39]
Thomas-Moya E, Gianotti M, Proenza AM, et al. Paraoxonase 1 response to a high-fat diet: gender differences in the factors involved. Molecular medicine 2007; 13(3-4): 203-9.
[40]
Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 2009; 5(8)e1000602
[41]
Horvath S, Zhang Y, Langfelder P, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol 2012; 13(10): R97.
[42]
Ling C, Poulsen P, Simonsson S, et al. Genetic and epigenetic factors are associated with expression of respiratory chain component NDUFB6 in human skeletal muscle. J Clin Invest 2007; 117(11): 3427-35.
[43]
Sumi A, Nakamura U, Iwase M, et al. The gene-treatment interaction of paraoxonase-1 gene polymorphism and statin therapy on insulin secretion in Japanese patients with type 2 diabetes: Fukuoka diabetes registry. BMC Med Genet 2017; 18(1): 146.
[44]
Chistiakov DA, Melnichenko AA, Orekhov AN, et al. Paraoxonase and atherosclerosis-related cardiovascular diseases. Biochimie 2017; 132: 19-27.
[45]
Wu H, Jia Q, Liu G, et al. Decreased uric acid levels correlate with poor outcomes in acute ischemic stroke patients, but not in cerebral hemorrhage patients. J Stroke Cerebrovasc Dis 2014; 23(3): 469-75.
[46]
Marsillach J, Becker JO, Vaisar T, et al. Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis. J Proteome Res 2015; 14(5): 2046-54.